(Date:11/24/2009)... , SAN MATEO, Calif., Nov. 24 /PRNewswire... biopharmaceutical company focused on developing a..., announced today that Anthony DiTonno, President ...nt at the 21st Annual Piper Jaffray Health Care Co... York Palace Hotel in New York, New York. ,, M...
(Date:11/24/2009)... , SEATTLE, Nov. 24 Blue Marb...nd the Odessa Public Development Authority (OPDA) ...te,s Community Economic Revitalization Board (CERB... state,s first specialty biochemical biorefinery i...l significantly speed the development of our biore...
(Date:11/24/2009)... , , Primary efficacy endpoint has been m...nt endometrial cancer, , QUEBEC CITY, Nov. 24...ASDAQ: AEZS ; TSX: AEZ) (the "Company"), a global...erapy and oncology, today announced positive effic...totoxic peptide conjugate, AEZS-108 (formerly AN-1...
(Date:11/24/2009)... , DUBLIN, November 24 /PRNewswire-First...e global specialty biopharmaceutical company, toda...opean Medicines Agency for,velaglucerase alfa, the...nt,for the treatment of Type 1 Gaucher disease. Th...erase alfa that has been submitted, with previous,...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4...et Exchange Agreement, COPENHAGEN, September 13 ...n of an asset exchange agreement with,Medarex, Inc...ceive full,rights to HuMax-Inflam(TM)/MDX-018, whi...hts to multiple disease programs in oncology. Genm...iously held economic interests,in the assets excha...
...2 Schering-Plough,Corporation (NYSE: SGP ) annou...ggregate principal amount of 6.00% Senior Notes du...f 6.55% Senior Notes due 2037 through,an underwrit...pected to,close on Sept. 17, 2007, subject to cust...for the offering is Goldman, Sachs & Co. The,joint...
...2 PPD, Inc. (Nasdaq:,PPDI) today announced Daniel...ficer. He will assume his position on October 1. ... Honeywell,International, a $34 billion diversifie...st recently served as vice president and CFO of fi...s at Honeywell, he was CFO of,the company,s global...
Other Biology Technology:Genmab Announces Asset Exchange Agreement 2Schering-Plough Announces Pricing of Senior Notes Offering 2Schering-Plough Announces Pricing of Senior Notes Offering 3PPD Names Daniel Darazsdi as Chief Financial Officer 2PPD Names Daniel Darazsdi as Chief Financial Officer 3...ed for Optimal Microdissection , CapSure HS and C... extraction of populations of pure cells from tiss...e Microdissection., Ensure the Integrity of Micr... , All CapSure LCM Caps have a patented transfer ...
...n system is used for single-color real-time detect...rophores and features a real-time PCR thermal grad... from 96 wells, a gene expression macro for relati...is. The system includes the optical module and opt...
...ed for Optimal Microdissection , CapSure HS and C... extraction of populations of pure cells from tiss...e Microdissection., Ensure the Integrity of Micr... , All CapSure LCM Caps have a patented transfer ...
DNA Engine Opticon Continuous Fluorescence Detection System from Bio-Rad
Biology Products: